Table 4 Malignancy rate of AUS/FLUS thyroid cytopathology reported at various centers

Present Study

Canada

2014–19

18.1 (205/1130)

13.2 (24/182)

25.3% (24/95)

The Bethesda System [11]

N/A

2009

≤7

~ 5–15

N/A

The Bethesda System [18]

N/A

2017

≤10

~ 10–30

N/A

Bernstein et al. [19]

Canada

2010–13

12.0

37 (86/233)

46 (86/187)

Erivwo & Ghosh [20]

Canada

2010–13

5.5

29.8 (54/181)

N/A

Oosthuizen et al. [21]

Canada

2010–16

N/A

N/A

32 (30/93)

Williams et al. [22]

Canada

2006–10

18.8

N/A

24.7 (N/A)

Wu et al. [15]

United States

2006–08

27.2

N/A

6 (3/51)

Hong et al. [16]

South Korea

2011–14

N/A

10.2 (70/687)

72.9 (70/96)

Ho et al. [23]

United States

2008–11

8.0

26.6 (144/541)

37.8 (144/381)

Cavalheiro et al. [26]

Brazil

2010–14

N/A

N/A

15.7 (75/478)

Mileva et al. [27]

Republic of Macedonia

2012–16

5.9

N/A

31.2 (35/112)^a

Al-Abbadi et al. [28]

Saudi-Arabia

2010–14

4.4

N/A

29 (12/42)^a

Wong et al. [29]

United States

2008–12

9

N/A

33.1 (60/181)

Yaprak Bayrak et al. [30]

Turkey

2012–17

4.2

N/A

25.0 (27/108)

Sullivan et al. [31]

United States

2003–12

6

17 (56/332)

33 (56/168)

Topaloglu et al. [32]

Turkey

N/A

N/A

N/A

23.4 (105/449)

Vanderlaan et al. [33]

United States

2005–09

10.9

29.0 (96/331)^a

48.2 (96/199)